Heartflow announced that it has released new clinical evidence and launched the NAVIGATE‑PCI registry at the American College of Cardiology Annual Scientific Session. The company presented data from a 15,000‑patient registry that demonstrates high plaque volume independently predicts a fourfold increase in major adverse cardiovascular events, regardless of conventional risk factors or stenosis severity. This finding underscores the clinical value of Heartflow’s AI‑driven plaque analysis and supports broader adoption of its diagnostic platform.
The launch of the NAVIGATE‑PCI registry represents a significant step toward building a robust real‑world evidence base for Heartflow’s technology. "The Heartflow Plaque Analysis data presented at ACC and the launch of the NAVIGATE‑PCI Registry represent important steps in building the rigorous real‑world evidence needed to support AI‑driven decision‑making across the full continuum of cardiovascular care," said Dr. Campbell Rogers, Chief Medical Officer. The evidence positions Heartflow to strengthen payer coverage, differentiate itself from competitors, and accelerate market penetration.
Heartflow’s AI‑driven diagnostics have received FDA clearance for FFRCT in 2014 and for plaque analysis in 2022, and the company went public on Nasdaq in August 2025. The new registry data reinforce the company’s strategy to transform coronary artery disease into a condition that can be detected early, diagnosed accurately, and managed for life. By demonstrating that plaque volume is a powerful predictor of future events, Heartflow is bolstering the clinical and economic case for its platform and laying the groundwork for broader adoption across cardiology practices.
The announcement is a major operational milestone that expands Heartflow’s evidence base and supports its long‑term growth strategy. The data from the 15,000‑patient registry and the launch of the NAVIGATE‑PCI registry are expected to enhance the company’s competitive position and accelerate the adoption of its AI‑driven diagnostic tools across the cardiovascular care continuum.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.